Natco Pharma Limited · NSE:NATCOPHARM
Natco Pharma — Q2 FY2020-21 Earnings Presentation
18 slides from Natco Pharma's earnings presentation, Nov 16, 2020
Slide 1: Cover letter to BSE and NSE
November 16, 2020 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Sreet, Fort “Exchange Plaza”, Bandra – Kurla Complex Mumbai 400 001 Bandra (E) Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir, Please find enclosed he
Slide 2: Natco Pharma Limited Investor Presentation Q2 FY2020-21
NATCO PHARMA LIMITED INVESTOR PRESENTATION Q2, FY2020-21
Slide 3: Disclaimer/Important Disclosure
DISCLAIMER/IMPORTANT DISCLOSURE THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background i
Slide 4: Business Overview
BUSINESS OVERVIEW Vertically integrated pharmaceutical company with presence across geographies - India, US and ROW Strong brand position in domestic pharma segments - Largest pharmaceutical player in oncology with brands catering to diseases including breast, bone, lung and ovarian cancer - Leading
Slide 5: Performance at a Glance
PERFORMANCE AT A GLANCE Revenue(1) ROE (%) Ownership Structure(3) INR mn 22,424 22,247 29% 20,789 20,224 23% Public, Promoter, 10,897 51.09% 48.91% 18% 12% 12% FY2016 FY2017 FY2018 FY2019 FY2020 EBITDA & EBITDA Margins 25.9% 33.5% 43.2% 41.6% 34.1% FY2016 FY2017 FY2018 FY2019 FY2020 INR mn 9,688 9,2
Slide 6: Key Business Segments - Pharma
KEY BUSINESS SEGMENTS - PHARMA FORMULATIONS Domestic International Exports API (Domestic & Exports) Subsidiaries • Three key business segments: Oncology, ◼ Focused on niche opportunities in ◼ Strategically important division ◼ Operations in Brazil, Specialty Pharma, Cardiology and the US ◼ 39 active
Slide 7: US Market - Focus on Complex Generics
US MARKET- FOCUS ON COMPLEX GENERICS KEY PRODUCTS IN THE PORTFOLIO STRATEGY FOR US MARKETS Therapeutic Segment / Primary Key Brand Molecule ◼ Predominantly focused on high-barrier-to-entry products that are Indication typically characterized by one or more of the following Current Portfolio Copaxone
Slide 8: Strong Growth in Domestic Business
STRONG GROWTH IN DOMESTIC BUSINESS DOMESTIC PRODUCT LAUNCHES IN FY 2020 DOMESTIC FORMULATION SALES(1) ◼ Launched 8 products during the year. Target to launch 6-8 products a year. INR mn ◼ Positioned #1 in sales of branded oncology medicines in India. ◼ Market leading positions across the Hep-C class
Slide 9: Strong Market Position in Domestic Oncology Segment
STRONG MARKET POSITION IN DOMESTIC ONCOLOGY SEGMENT OVERVIEW OF ONCOLOGY DIVISION ONCOLOGY REVENUE ◼ Over 15 years of strong presence in oncology segment. One of the leaders in the sale of branded oncology medicines in India. INR mn 3,968 ◼ Portfolio of well recognized brands – 8 brands with INR 100
Slide 10: Expanding ROW Presence
EXPANDING ROW PRESENCE CANADA ◼ Strong portfolio with 20+ products including Oncology, cardiovascular and CNS therapies ◼ 18 approvals in place ◼ Several potential sole/limited generic products filed SUBSIDIARIES PERFORMANCE BRAZIL ◼ Sole generic of Everolimus tablets for the 2nd consecutive year IN
Slide 11: API Facilities
API FACILITIES STRENGTHS ◼ Strategically important business – develops APIs primarily for third party sales and also for captive ▪ Well established process safety engineering lab consumption ▪ Complex multi-step synthesis & scale-up ◼ Portfolio of 39 active US DMFs with niche products under developm
Slide 12: Research & Development Capabilities
RESEARCH & DEVELOPMENT CAPABILITIES R&D capabilities demonstrated by its complex and niche product filings in formulations and API segments ◼ Two research facilities with capabilities across synthetic chemistry, biotech & fermentation, nano pharmaceuticals, new drug FINISHED DOSAGE discovery & cell
Slide 13: Formulation Facilities
FORMULATION FACILITIES INTERNATIONAL MARKETS KOTHUR VISAKHAPATNAM ◼ Oral and solid dosages including ◼ Solid oral tablet and capsule cytotoxic Orals, cytotoxic manufacturing injectables and pre-filled syringes ◼ Site approval received from USFDA. First ◼ USFDA, GMP, (DCA), German, Health product app
Slide 14: Crop Health Sciences
CROP HEALTH SCIENCES TECHNICAL UNIT ◼ Strategically Initiated greenfield manufacturing facilities for producing Niche Agrichemical products in the Nellore District of Andhra Pradesh in January 2019 with a total capital expenditure of INR 100 crores ◼ Leveraging on our strengths in synthetic chemistr
Slide 15: Key Management
KEY MANAGEMENT V.C Nannapaneni ◼ Holds a Masters degree in Pharmaceutical Administration from the Long Island University, USA Chairman and Managing Director ◼ Over 4 decades of experience in the pharmaceutical industry Rajeev Nannapaneni ◼ Holds a Bachelors degree in Quantitative Economics and Histo
Slide 16: Consolidated Financials
CONSOLIDATED FINANCIALS Consolidated Profit & Loss Statement (INRmn) Consolidated Balance Sheet (INRmn) Particulars 31 March 2020 31 March 2019 Particulars 31 March 2020 31 March 2019 Income I ASSETS 1 Revenue from operations 19,150 20,945 (1) Non-current assets 2 Other income 1,074 1,302 (a) Proper
Slide 17: Quarterly Financial Summary
QUARTERLY FINANCIAL SUMMARY SEGMENTAL BREAKDOWN (INR Mn)z CONSOLIDATED FINANCIAL RESULTS (INR Mn) Q2FY21 Q2FY20 FY20 FY19 Revenue Division Q2FY21 Q2FY20 FY20 FY19 Total Revenues 8,279 5,189 20,225 22,247 A) API Revenue(1):- 1,995 947 3,553 3,019 EBITDA 3,021 1,675 6,900 9,250 B) Formulation:- EBITDA
Slide 18: A View of the Eco-Park at Natco's API Facility
Contact Investor Relations Team at ir@natcopharma.co.in 040-2354 7532; Extn 220 A VIEW OF THE ECO-PARK AT NATCO’S API FACILITY 17